Literature DB >> 24399786

Cancer statistics, 2014.

Rebecca Siegel1, Jiemin Ma, Zhaohui Zou, Ahmedin Jemal.   

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data were collected by the National Center for Health Statistics. A total of 1,665,540 new cancer cases and 585,720 cancer deaths are projected to occur in the United States in 2014. During the most recent 5 years for which there are data (2006-2010), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.4% per year in women. The combined cancer death rate (deaths per 100,000 population) has been continuously declining for 2 decades, from a peak of 215.1 in 1991 to 171.8 in 2010. This 20% decline translates to the avoidance of approximately 1,340,400 cancer deaths (952,700 among men and 387,700 among women) during this time period. The magnitude of the decline in cancer death rates from 1991 to 2010 varies substantially by age, race, and sex, ranging from no decline among white women aged 80 years and older to a 55% decline among black men aged 40 years to 49 years. Notably, black men experienced the largest drop within every 10-year age group. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population.
© 2014 American Cancer Society, Inc.

Entities:  

Keywords:  cancer; epidemiology; health disparities; incidence; survival; trends

Mesh:

Year:  2014        PMID: 24399786     DOI: 10.3322/caac.21208

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.

Authors:  Francisco Osvaldo García-Pérez; Jenny Davanzo; Sergio López-Buenrostro; Clara Santos-Cuevas; Guillermina Ferro-Flores; Miguel A Jímenez-Ríos; Anna Scavuzzo; Zael Santana-Ríos; Sevastián Medina-Ornelas
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  Sortilin regulates progranulin action in castration-resistant prostate cancer cells.

Authors:  Ryuta Tanimoto; Alaide Morcavallo; Mario Terracciano; Shi-Qiong Xu; Manuela Stefanello; Simone Buraschi; Kuojung G Lu; Demetrius H Bagley; Leonard G Gomella; Katia Scotlandi; Antonino Belfiore; Renato V Iozzo; Andrea Morrione
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

Review 3.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

4.  Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.

Authors:  Lamiss Mohamed Abd el Aziz
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

Review 5.  Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer.

Authors:  Gary R Epler; Eileen M Kelly
Journal:  Oncologist       Date:  2014-10-31

6.  Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.

Authors:  Min-Li Mo; Jie Ma; Zhao Chen; Bing Wei; Hui Li; Yong Zhou; Huaiyin Shi; Bhairavi Tolani; Joy Q Jin; Hsin-Hui Tseng; Dong Shen; Yi Zhan; Jun Li; David M Jablons; Rong-Qing Zhang; Yongjun Guo; Biao He; Hai-Meng Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-04       Impact factor: 4.553

7.  Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

Authors:  Bin Wang; U-Ging Lo; Kaijie Wu; Payal Kapur; Xiangyang Liu; Jun Huang; Wei Chen; Elizabeth Hernandez; John Santoyo; Shi-Hong Ma; Rey-Chen Pong; Dalin He; Yi-Qiang Cheng; Jer-Tsong Hsieh
Journal:  Int J Cancer       Date:  2017-07-31       Impact factor: 7.396

8.  Emotional approach coping and depressive symptoms in colorectal cancer patients: The role of the intimate relationship.

Authors:  Jennifer Barsky Reese; Stephen J Lepore; Elizabeth A Handorf; Jennifer A Haythornthwaite
Journal:  J Psychosoc Oncol       Date:  2017-05-16

9.  Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Authors:  Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram
Journal:  Laryngoscope       Date:  2016-08-31       Impact factor: 3.325

10.  Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.

Authors:  Agnieszka A Rucki; Qian Xiao; Stephen Muth; Jianlin Chen; Xu Che; Jennifer Kleponis; Rajni Sharma; Robert A Anders; Elizabeth M Jaffee; Lei Zheng
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.